Investors Research Corp Eli Lilly & CO Transaction History

Investors Research Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	BUY	$525.19 - $619.13 $3,151 - $3,714	6 New	6 $3,000
Q2 2022 Jul 21, 2022	SELL	$278.73 - $327.27 $27,873 - $32,727	-100 Reduced 5.32%	1,780 $577,000
Q1 2022 Apr 13, 2022	BUY	$234.69 - $291.66 $3,755 - $4,666	16 Added 0.86%	1,880 $538,000
Q2 2021 Jul 29, 2021	BUY	$180.55 - $233.54 $18,055 - $23,354	100 Added 5.67%	1,864 $428,000
Q3 2019 Oct 22, 2019	BUY	$106.79 - $116.16 $9,931 - $10,802	93 Added 5.57%	1,764 $197,000
Q1 2019 Apr 23, 2019	BUY	$111.31 - $131.02 $185,999 - $218,934	1,671 New	1,671 $217,000

4,010

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Investors Research Corp, based on Form 13F filings with the SEC.

Stay updated on Investors Research Corp with notifications on news.